Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ropeginterferon Alfa-2b and Azacitidine in MDS/AML With TP53 Mutations
NCT07646821Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 2, open-label trial of ropeginterferon alfa-2b in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Safety and adverse events at 1 year. Started Oct 2026; status: recruiting.
02
Drugs
ropeginterferon alfa-2b
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07646821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07646821.